Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
- Associated Therapies
- -
Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2007-12-06
- Lead Sponsor
- Università degli Studi dell'Insubria
- Target Recruit Count
- 30
- Registration Number
- NCT00564057
- Locations
- 🇮🇹
University of Insubria, Department of Clinical Medicine, Varese, Italy
CCB Safety Study in Treatment of Hypertension of ADPKD
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2007-10-18
- Lead Sponsor
- Kyorin University
- Target Recruit Count
- 150
- Registration Number
- NCT00541853
- Locations
- 🇯🇵
Toranomon Hospital, Kidney center, Tokyo, Japan
🇯🇵Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
🇯🇵Department of Urology, Teikyo University, School of Medicine, Tokyo, Japan
A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 360
- Registration Number
- NCT00538486
- Locations
- 🇨🇳
The third hospital affiliated to the Third Military Medical University, Chongqing, China
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
- Conditions
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2207
- Registration Number
- NCT00434967
- Locations
- 🇸🇰
Research Site, Sahy, Slovakia
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
- Conditions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2007-02-02
- Lead Sponsor
- Charles University, Czech Republic
- Registration Number
- NCT00430833
- Locations
- 🇨🇿
Cardiocenter, Third Faculty of Medicine, Charles University, Prague, Czech Republic
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
- Conditions
- Interventions
- Drug: CaptoprilDrug: EnalaprilDrug: LisinoprilDrug: RamiprilDrug: TrandolaprilDrug: BisoprololDrug: CarvedilolDrug: Metoprolol succinateDrug: CandesartanDrug: ValsartanDrug: EplerenoneDrug: SpironolactoneDrug: DiureticsDrug: HF treatment according to Swedish guidelinesProcedure: Blood samplesProcedure: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 252
- Registration Number
- NCT00391846
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
- Conditions
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2008-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1979
- Registration Number
- NCT00383929
- Locations
- 🇩🇪
Research SIte, Hann, Germany
🇬🇧Research Site, Wokingham, United Kingdom
Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
- Conditions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2006-08-07
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 600
- Registration Number
- NCT00360763
- Locations
- 🇨🇳
Department of Cardiology, Wuhan Union Hospital, Wuhan, Hubei, China
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2012-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 315
- Registration Number
- NCT00348686
- Locations
- 🇰🇷
Research Site, Ulsan, Korea, Republic of
Diabetes Type 1, Treatment Study Atacand/Placebo After Kidney Biopsy
- Conditions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2006-05-19
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 13
- Registration Number
- NCT00328302
- Locations
- 🇸🇪
Childrens Hospital, Karolinska University Hospital, Huddinge, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.